Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year ...

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.

Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass is a newly founded British company that is moving to commercialize the long-studied therapeutic impact of psilocybin. Both market acceptance issues and bad trip potential are risks of its ...

Shares of Compass Pathways (CMPS 3.62%) have soared since the company's recent stock market debut as support grows for the use of popular recreational drugs to combat depression. Can the highly ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

This article was originally published on PSYCH and appears here with permission. UK-based COMPASS Pathways (NASDAQ:CMPS) recently published data from its Phase IIb trials, with COMP360 psilocybin ...

Compass Pathways has seen its shares slide in a big way this year. The drugmaker, however, has made significant progress on the clinical front in 2021. This clinical-stage biopharma could be a big ...

COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its ...

Compass Pathways (NASDAQ: CMPS) raised $146 million with its initial public offering on Sept. 18. While the IPO's price was set at $17, on the first day of trading, it opened at $23.40 and closed the ...